Testing for the existence of a desirable dose combination

Area of Science:

• Clinical Trials
• Biostatistics
• Pharmacology

Background:

• Evaluating drug combinations is crucial for therapeutic advancement.
• Multilevel factorial clinical trials are complex designs for studying multiple drug doses.
• Identifying synergistic drug combinations requires robust statistical methods.

Purpose of the Study:

• To develop and evaluate statistical tests for assessing the efficacy of drug combinations.
• To determine if any dose combination of two drugs shows superior therapeutic effect compared to individual components.
• To address the challenges posed by nuisance parameters in the distribution of test statistics.

Main Methods:

• Construction of two novel test statistics for comparing drug combinations against component doses.
• Derivation of significance levels for the proposed tests.
• Analysis of power functions and their behavior with varying nuisance parameters.
• Development of alpha-level tests and provision of critical values.

Main Results:

• The power of the proposed tests is maximized when nuisance parameters (mean differences between component drug doses) approach infinity.
• Significance levels were derived, leading to the proposal of two alpha-level tests.
• Tables of critical values are provided for practical application.
• Insights into the power performance of the tests were gained through analysis.

Conclusions:

• The study provides statistically sound methods for evaluating drug combinations in clinical trials.
• The proposed alpha-level tests offer a reliable approach to identifying effective combination therapies.
• The findings contribute to optimizing the design and analysis of multilevel factorial clinical trials.